Announcement

Collapse
No announcement yet.

China - Poultry vaccine ready for the new H9 epidemic strain - March 30, 2017

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • China - Poultry vaccine ready for the new H9 epidemic strain - March 30, 2017

    PREPARO BIO - ENGINEERING CO., LTD. Announcement on obtaining certificate of registration of new veterinary drugs


    At 05:04 on March 30, 2017 Securities Daily 0Weibomicro-channelQQ spaceto add favorite


      The board of directors and all directors of the Company warrant that there are no false representations, misleading statements or material omissions contained in this announcement and shall be jointly and severally liable for the authenticity, accuracy and completeness of the contents of this announcement.
    (26.110, -0.52, -1.95%)
      First, the basic information of the new veterinary drug
      New veterinary drug name: Chicken Newcastle disease, avian influenza (H9 subtype) inactivated vaccine (La Sota strain + SZ strain)
      Registration Category: Three categories
      Main Ingredients: Inactivated Chicken Newcastle Disease Virus La Sota Strain, H9 Subtype Avian Influenza Virus SZ Strain.
      Role and use: for the prevention of chicken Newcastle disease and H9 subtype of avian influenza. The immunization period is 6 months.
      Usage and Dosage: Subcutaneous or intramuscular injection. 14 to 35 days old chickens, each 0.15mL; 35 days old chickens, each 0.3mL.
      Second, the new veterinary drug research and development situation
      The product was submitted to the Ministry of Agriculture for the first time on September 1, 2014, and the Ministry of Agriculture announced the issuance of a new veterinary drug registration certificate on March 28, 2017 by the subsequent clinical trials and the registration of new veterinary drugs. The project invested R & D costs 1,862,500 yuan.
      Third, the new veterinary drug related market background situation
      Chicken Newcastle disease, H9 subtype avian influenza is a serious harm to our country and the world's poultry industry, an important disease, with a wide range of widespread, high incidence of mixed infection in the high mortality rate, to the chicken industry caused huge economic losses , The world's veterinary and chicken companies attach great importance to it, the current epidemic mainly to the main vaccine prevention. At present, the domestic production of chickens Newcastle disease, H9 subtype avian influenza two inactivated vaccine companies have 40 (including the company), according to "veterinary drug industry development report" shows that the enterprises in 2013, 2014, 2015 market Sales of new - flow (H9 subtype) in the amount of inactivated vaccine were 168 million yuan, 208 million yuan, 217 million yuan, the company in 2013, 2014, 2015 sales of the amount of the product were 1,783.17 million , 2,125.55 million, 2,749.76 million yuan.
      At present, the domestic production of chickens Newcastle disease-H9 subtype of avian influenza two inactivated vaccine more enterprises, but most of the enterprises used in the H9 subtype avian influenza vaccine strains are separated from the age of the earlier strains, and H9 subtype Avian influenza virus has the characteristics of fast mutation, resulting in the existing vaccine strains and the genetic distance between the larger strains, so the need to update the vaccine strain. The above-mentioned new products developed by the company use the current popular H9 subtype avian influenza SZ strain antigen cross-protection spectrum broad, the current epidemic strains can produce better immune protection; in the vaccine production process, through the antigen enrichment technology and new Adjuvant technology, can significantly reduce the immune dose of the vaccine, reduce the stress on the chicken body, the future market prospects.
      Fourth, the new veterinary drugs before the listing still need to perform the procedure
      In accordance with the "Veterinary Drug Administration Regulations", "veterinary drug product approval number management approach" and other relevant provisions of the product before listing, should also be issued by the Ministry of Agriculture issued a veterinary drug product approval number.
      Fifth, the new veterinary drug development success on the company's significance and contribution
      The new veterinary drug certificate is the company continued to attach importance to scientific and technological innovation, increase the results of R & D investment, and further reflects the company's innovative strength, but also to promote the industry poultry vaccine products upgrading, enriching the company's product category, In the poultry market vaccine innovation leading position, and effectively enhance the company's overall competitiveness in the industry, the company will bring new performance growth.
      Special announcement.
      Pleasant Bioengineering Co., Ltd. Board of Directors
      March 29, 2017

      Stock Code: 603566 Securities referred to: Pulai Ke Announcement No .: 2017-003
      PREPARO BIO - ENGINEERING CO., LTD. Announcement on obtaining certificate of registration of new veterinary drugs




    zhttp://finance.sina.com.cn/roll/2017-03-30/doc-ifycwyxr8698563.shtml
Working...
X